Conferences - Results from #620

Viewing 621-640 of 11869 articles

AUA 2024: Long Term Outcomes of Low and Intermediate Risk Bladder Cancer Patients Treated with Transurethral Resection Eligible for Active Surveillance

AUA 2024: Intravesical Instillations in Octogenarian High Grade, Non Muscle-Invasive Bladder Cancer Patients: Could They Offer a Real Survival Advantage?

AUA 2024: Head-to-Head Oncological Outcomes Comparison of Mitomycin C vs BCG Treatment in Intermediate-Risk Non-Muscle Invasive Bladder Cancer Patients

AUA 2024: Major Complications and Adverse Events of SpaceOAR Hydrogel: An Analysis of the Manufacturer and User Facility Device Experience Database

AUA 2024: Cancer Control Rates in Adequate Versus Inadequate Treatment with Adjuvant Immunotherapy Instillations with BCG

AUA 2024: Review of SpaceOAR Complications in The MAUDE Database with Focus on Rectal Wall Infiltration

AUA 2024: Survey on Clinical Practice Patterns in the United States for Using Intravesical Chemotherapy in the Management of BCG Unresponsive Non-Muscle Invasive Bladder Cancer

AUA 2024: First Safety and Efficacy Results of the TAR-210 Erdafitinib Intravesical Delivery System in Patients with Non–muscle-Invasive Bladder Cancer with Select FGFR Alterations

AUA 2024: Temporal and Regional Patterns of Prostate Cancer Positron Emission Tomography Imaging Among Commercial Insurance Beneficiaries in the United States

AUA 2024: Efficacy of Nadofaragene Firadenovec-vncg for Patients With Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Final Results From a Phase 3 Trial

AUA 2024: PSMA-PET Guided Metastasis Directed Therapy for Oligometastatic Prostate Cancer

AUA 2024: Exploring Recurrence After Initial Response to UGN-101 Induction in Expanded Settings

AUA 2024: Use of Blue Light Cystoscopy Among Non-Muscle Invasive Bladder Cancer Patients and Outcomes in an Equal Access setting: A Propensity Scored Matched Analysis

AUA 2024: Genetic Testing in Prostate Cancer: The Role of the Urologists

AUA 2024: BOND-003- Cohort P: A Multi-National, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

AUA 2024: Prostate Cancer: Dissemination and Availability of Minimally Invasive Treatments to Underserved Populations

AUA 2024: PIVOT-006: A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec versus Surveillance for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer Following Transurethral Resection of Bladder Tumor

AUA 2024: SSANTROP (APRO07-2022): A Phase II Prospective, Open-Label, Multi-Center, Single Arm Study of Sasanlimab + Sacituzumab Govitecan in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Patients

AUA 2024: QUILT-2.005: A Comparison of Intravesical BCG in Combination with the IL-15 Superagonist N-803 to BCG Alone in Patients with BCG-Naïve NMIBC

AUA 2024: Sequential Endoluminal Gemcitabine and Docetaxel Versus Bacillus Calmette–Guérin for the Treatment of High-Grade Upper Tract Urothelial Carcinoma

27
28
29
30
31
32
33
34
35
36